BackgroundLymph node metastasis (LNM) is a critical risk factor affecting treatment strategy and prognosis in patients with early‐stage cervical cancer.PurposeTo establish a multiparametric MRI (mpMRI)‐based radiomics nomogram for preoperatively predicting LNM status.Study TypeRetrospective.PopulationAmong 233 consecutive patients, 155 patients were randomly allocated to the primary cohort and 78 patients to the validation cohort.Field StrengthRadiomic features were extracted from a 1.5T mpMRI scan (T1‐weighted imaging [T1WI], fat‐saturated T2‐weighted imaging [FS‐T2WI], contrast‐enhanced [CE], diffusion‐weighted imaging [DWI], and apparent diffusion coefficient [ADC] maps).AssessmentThe performance of the nomogram was assessed with respect to its calibration, discrimination, and clinical usefulness. The area under the receiver operating characteristics curve (ROC AUC), accuracy, sensitivity, and specificity were also calculated.Statistical TestsThe least absolute shrinkage and selection operator (LASSO) method was used for dimension reduction, feature selection, and radiomics signature building. Multivariable logistic regression analysis was used to develop the radiomics nomogram. An independent sample t‐test and chi‐squared test were used to compare the differences in continuous and categorical variables, respectively.ResultsThe radiomic signature allowed a good discrimination between the LNM and non‐LNM groups, with a C‐index of 0.856 (95% confidence interval [CI], 0.794–0.918) in the primary cohort and 0.883 (95% CI, 0.809–0.957) in the validation cohort. Additionally, the radiomics nomogram also had a good discriminating performance and yielded good calibration both in the primary and validation cohorts (C‐index, 0.882 [95% CI, 0.827–0.937], C‐index, 0.893 [95% CI, 0.822–0.964], respectively). Decision curve analysis demonstrated that the radiomics nomogram was clinically useful.Data ConclusionA radiomics nomogram was developed by incorporating the radiomics signature with the MRI‐reported LN status and FIGO stage. This nomogram might be used to facilitate the individualized prediction of LNM in patients with early‐stage cervical cancer.Level of Evidence3Technical Efficacy Stage2 J. Magn. Reson. Imaging 2020;52:885–896.

BackgroundPreoperative differentiation of borderline from malignant epithelial ovarian tumors (BEOT from MEOT) can impact surgical management. MRI has improved this assessment but subjective interpretation by radiologists may lead to inconsistent results.PurposeTo develop and validate an objective MRI‐based machine‐learning (ML) assessment model for differentiating BEOT from MEOT, and compare the performance against radiologists' interpretation.Study TypeRetrospective study of eight clinical centers.PopulationIn all, 501 women with histopathologically‐confirmed BEOT (n = 165) or MEOT (n = 336) from 2010 to 2018 were enrolled. Three cohorts were constructed: a training cohort (n = 250), an internal validation cohort (n = 92), and an external validation cohort (n = 159).Field Strength/SequencePreoperative MRI within 2 weeks of surgery. Single‐ and multiparameter (MP) machine‐learning assessment models were built utilizing the following four MRI sequences: T2‐weighted imaging (T2WI), fat saturation (FS), diffusion‐weighted imaging (DWI), apparent diffusion coefficient (ADC), and contrast‐enhanced (CE)‐T1WI.AssessmentDiagnostic performance of the models was assessed for both whole tumor (WT) and solid tumor (ST) components. Assessment of the performance of the model in discriminating BEOT vs. early‐stage MEOT was made. Six radiologists of varying experience also interpreted the MR images.Statistical TestsMann–Whitney U‐test: significance of the clinical characteristics; chi‐square test: difference of label; DeLong test: difference of receiver operating characteristic (ROC).ResultsThe MP‐ST model performed better than the MP‐WT model for both the internal validation cohort (area under the curve [AUC] = 0.932 vs. 0.917) and external validation cohort (AUC = 0.902 vs. 0.767). The model showed capability in discriminating BEOT vs. early‐stage MEOT, with AUCs of 0.909 and 0.920, respectively. Radiologist performance was considerably poorer than both the internal (mean AUC = 0.792; range, 0.679–0.924) and external (mean AUC = 0.797; range, 0.744–0.867) validation cohorts.Data ConclusionPerformance of the MRI‐based ML model was robust and superior to subjective assessment of radiologists. If our approach can be implemented in clinical practice, improved preoperative prediction could potentially lead to preserved ovarian function and fertility for some women.Level of EvidenceLevel 4.Technical EfficacyStage 2. J. Magn. Reson. Imaging 2020;52:897–904.

No abstract

DCE-MRI with volume quantification is a technically feasible method, and can be used for the differentiation of ovarian tumors and for discriminating between type I and type II EOCs.

No abstract